stockportfolio.pro
Stocks / ABCL vs MBX
ABCL vs MBX
AbCellera Biologics Inc. and MBX Biosciences, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| AbCellera Biologics Inc. (ABCL) | MBX Biosciences, Inc. (MBX) | |
|---|---|---|
| Market cap | $1.6B | $1.6B |
| Revenue (latest FY) | $75.13M | $0 |
| Net income (latest FY) | $-146.41M | $-86.97M |
| Revenue growth (5y CAGR) | -20.3% | — |
| Net margin | -194.9% | — |
| Return on equity | -15.1% | -23.6% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ABCL — free Open MBX — freeFrequently asked questions
Which is bigger, ABCL or MBX?
MBX Biosciences, Inc. is larger by market capitalization — $1.6B versus $1.6B.
Which grows faster, ABCL or MBX?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.